CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic
Authors
E Badmus
JA Cooper
+8 more
M Futema
SE Humphries
F Karpe
A Kiley
SE Leigh
HAW Neil
LK Steel
RA Whittall
Publication date
1 January 2013
Publisher
Doi
Cite
View
on
PubMed
Abstract
Aim: To determine the frequency and spectrum of mutations causing Familial Hypercholesterolaemia (FH) in patients attending a single UK specialist hospital lipid clinic in Oxford and to identify characteristics contributing to a high mutation detection rate. Methods: 289 patients (272 probands) were screened sequentially over a 2-year period for mutations in LDLR, APOB and PCSK9 using standard molecular genetic techniques. The Simon Broome (SB) clinical diagnostic criteria were used to classify patients and a separate cohort of 409 FH patients was used for replication. Results: An FH-causing mutation was found in 101 unrelated patients (LDLR=54 different mutations, APOB p.(Arg3527Gln)=10, PCSK9 p.(Asp374Tyr)=0). In the 60 SB Definite FH patients the mutation detection rate was 73% while in the 142 with Possible FH the rate was significantly lower (27%, p<0.0001), but similar (14%, p=0.06) to the 70 in whom there was insufficient data to make a clinical diagnosis. The mutation detection rate varied significantly (p=9.83×10-5) by untreated total cholesterol (TC) levels (25% in those <8.1mmol/l and 74% in those >10.0mmol/l), and by triglyceride levels (20% in those >2.16mmol/l and 60% in those <1.0mmol/l (p=0.0005)), with both effects confirmed in the replication sample (p for trend=0.0001 and p=1.8×10-6 respectively). There was no difference in the specificity or sensitivity of the SB criteria versus the Dutch Lipid Clinic Network score in identifying mutation carriers (AROC respectively 0.73 and 0.72, p=0.68). Conclusions: In this genetically heterogeneous cohort of FH patients the mutation detection rate was significantly dependent on pre-treatment TC and triglyceride levels. © 2013 The Authors
Similar works
Full text
Available Versions
Supporting member
Oxford University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ora.ox.ac.uk:uuid:97517933...
Last time updated on 30/09/2015
Oxford University Research Archive (ORA)
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 18/04/2020
ORA - Oxford University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ora.ox.ac.uk:uuid:fad8268a...
Last time updated on 13/04/2022
Oxford University Research Archive (ORA)
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 18/04/2020
Supporting member
Oxford University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ora.ox.ac.uk:uuid:fad8268a...
Last time updated on 30/09/2015